Role of Nrf2 and Its Activators in Cardiocerebral Vascular Disease

Table 3

Clinical trials of Nrf2 activators.

Name	Registration no.	Target disease	Status	Study period
Sulforaphane	NCT02614742	SAH	Phase 2	Apr. 2016-Mar. 2019
	NCT02801448	Type 2 diabetes	Phase 2	Sept. 2015-Jun. 2020
	NCT02970682	Breast neoplasm	Phase 2	Oct. 2016-Jan. 2019
Bardoxolone methyl	NCT03068130	Pulmonary hypertension	Phase 3	Apr. 2017-Dec. 2021
	NCT00811889	Chronic kidney disease/type 2 diabetes	Phase 2	Apr. 2009-May 2010
	NCT00664027	Diabetic nephropathy	Phase 2	Apr. 2008-May 2009
Tecfidera	NCT00451451	Multiple sclerosis	Launched	Jun. 2007-Aug. 2011
Epigallocatechin gallate	NCT02015312	Cardiac amyloid light-chain amyloidosis	Phase 2	Apr. 2013-Oct. 2017
	NCT01923597	Diabetic nephropathy/hypertension	Phase 2	Nov. 2013-Mar. 2015
	NCT02731495	Traumatic brain injury	Phase 2/3	Mar. 2015-Nov. 2015
Dimethyl fumarate	NCT02461069	Multiple sclerosis	Phase 4	May. 2015-Jan. 2018
	NCT02784834	Chronic lymphocytic leukemia	Phase 1	Jun. 2016-Feb. 2019
	NCT02546440	Cutaneous T cell lymphoma	Phase 2	Sept. 2015-Sept. 2020
NBP	NCT00724724	Stroke	Phase 4	Aug. 2008-Jun. 2011
	NCT02149875	Acute ischemic stroke	Phase 1/2	Jan. 2010-May 2010
Andrographolide	NCT03132623	Acute bronchitis	Phase 4	Dec. 2016-Dec. 2017
	NCT02644590	Diabetes mellitus/type 1 hypertension	Phase 1	Feb. 2016-Sept. 2016